Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Evaluation of Immunohistochemical Expression of Human Epidermal Growth Factor Receptor 2 (HER 2) and Its Association With Clinicopathological Variables in Patients With Pancreatic Duct Adenocarcinoma in Upper Egypt

ID
Name
Soh-Med-23-09-4PD
Description
Pancreatic duct adenocarcinoma is a highly aggressive carcinoma that is associated with a poor prognosis. Detection of novel biological markers that are specifically over expressed in pancreatic duct adenocarcinoma and their subsequent targeting by anti cancer therapeutic modalities may improve patient's survival.
Trial arms
Trial start
2017-01-01
Estimated PCD
2020-08-31
Trial end
2020-12-31
Status
Completed
Treatment
immunohistochemical approach
Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.
Size
37
Primary endpoint
correlation of HRE-2 expression with clinical and pathological parameters
6 months
Eligibility criteria
Inclusion Criteria: 1. Cases of PDAC who underwent radical operations. 2. Tissue blocks with sufficient material. 3. Cases with available clinical data. Exclusion Criteria: 1. Cases of pancreatic carcinoma other than PDAC. 2. Patients who received preoperative chemotherapy or radiotherapy. 3. Patients with PDAC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations. 4. Cases with insufficient/destructed material. 5. Patients with inadequate clinical data.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 37, 'type': 'ACTUAL'}}
Updated at
2023-09-28

1 organization

1 product

1 indication

Organization
Sohag University
Product
Immunohistochemical approach
Indication
Pancreatic adenocarcinoma